Quick Answer
BriaCell Therapeutics Corp. reported Earnings Per Share Diluted of $62.19 (loss) per share for the year ending 2025.
- BriaCell Therapeutics Corp. showed a decrease of -42.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from BriaCell Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on October 16, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $0.04 per share | Q2 2022: $0.65 (loss) per share | Q4 2022: $0.07 (loss) per share | Q1 2023: $0.77 (loss) per share | Q2 2023: $0.32 (loss) per share | Q4 2023: $0.50 (loss) per share | Q1 2024: $10.64 (loss) per share | Q2 2024: $1.61 per share | Q4 2024: $32.67 (loss) per share | Q1 2025: $2.33 (loss) per share | Q2 2025: $1.64 (loss) per share | Q4 2025: $4.35 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), BriaCell Therapeutics Corp.'s Earnings Per Share Diluted has declined by 3,494.8%.
- Historical annual values: Fiscal year 2025: $62.19 (loss) per share | Fiscal year 2024: $43.68 (loss) per share | Fiscal year 2023: $1.30 (loss) per share | Fiscal year 2022: $1.73 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: